Alimera Sciences Inc(NASDAQ:ALIM) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $9.56M. Analysts estimated a revenue of $8.42M. Earnings per share were $-0.17. Analysts had estimated an EPS of $-0.19.
In a different note, On May 6, 2016, Cowen & Company said it Downgrades its rating on Alimera Sciences Inc. The shares have been rated ‘Market Perform’ by the firm.
Alimera Sciences Inc (ALIM) remained unchanged at the close of Friday session. Even as the volume increased to 4,00,685 ,the shares failed to make any impression and ended at 0 points or 0.00% at $1.65. The trading session commenced at $1.66 and the stock hit a high of $1.73 and touched $1.6 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $5.15 and the 52-week low is $1.015. The company has a market cap of $76 M and has approximately 4,57,59,253 outstanding shares.
Several Insider Transactions has been reported to the SEC. On Dec 17, 2015, Richard S Jr Eiswirth (COO and CFO) sold 46,669 shares at $2.31 per share price.Also, On Nov 16, 2015, C. Daniel Myers (President and CEO) sold 2,000 shares at $4.37 per share price.On Sep 8, 2015, Calvin W. Roberts (director) purchased 6,424 shares at $3.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Alimera Sciences Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research development and commercialization of prescription ophthalmic pharmaceuticals. The Company focuses on diseases affecting the back of the eye or retina. The Company’s commercial product is ILUVIEN which has been developed to treat diabetic macular edema (DME). ILUVIEN has received marketing authorization in the United States Austria Belgium the Czech Republic Denmark Finland France Germany Ireland Italy Luxembourg the Netherlands Norway Portugal Spain Sweden and the United Kingdom. In the United States ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the EU countries it is indicated for the treatment of vision impairment associated with DME.